Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of three small molecule drugs—silodosin, tamsulosin, and tadalafil. Silodosin and tamsulosin are both selective alpha-1 adrenergic receptor antagonists (alpha-blockers), primarily used to treat lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor, commonly used for erectile dysfunction and also approved for LUTS/BPH. The rationale for combining these agents is to leverage their complementary mechanisms of action to improve urinary flow rates, reduce LUTS severity, and address concomitant erectile dysfunction in men. Clinical studies have shown that combinations such as silodosin plus tadalafil or tamsulosin plus tadalafil provide superior improvements in symptom scores and urinary flow compared to monotherapy with any single agent[2][4][5]. All three drugs act via distinct but synergistic pathways affecting smooth muscle tone in the prostate, bladder neck, urethra, and penile vasculature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silodosin + tamsulosin + tadalafil.